&w=3840&q=100)
US Bill lowers remittance tax from 5% to 3.5% for non-US citizens
The Donald Trump administration has lowered the proposed remittance tax rate it plans to impose on funds sent abroad by non-US citizens, including to India, from 5 per cent to 3.5 per cent. The change was introduced through an amendment to the 'One Big Beautiful Bill', which was passed by the US House of Representatives on Thursday. Non-US citizens include H-1B, L-1, and F-1 visa holders, as well as green card holders. US citizens and nationals are exempt from this tax. The Bill will now head to the Republican-majority Senate for final approval before it can be enacted into law. The original version of the Bill — spanning major reforms in income tax, health care, corporate taxation, and federal debt — included a 5 per cent excise duty on outward remittances, to be paid by the sender. It drew concern from immigrant communities and experts, especially given the volume of remittances flowing from the US to countries like India and Mexico. A government official speaking on condition of anonymity said the Bill if enacted, will have an impact on remittances into the country. 'The government has not made an assessment yet. No discussion has happened whether its removal can be a demand under the proposed India-US bilateral trade agreement,' the official said. India is the largest recipient of remittances from the US. It received $32.9 billion in 2023-24, with a 27.7 per cent share in the country's inward remittances, according to the Reserve Bank of India data. Overall, such remittances have more than doubled from $55.6 billion in 2010-11 to $118.7 billion in 2023-24. 'In the short term, we expect remittances to India to spike before the effective date of January 1, 2026. We may also see a shift of some remittances from formal to informal channels,' said Lloyd Pinto, Partner - US Tax at Grant Thornton Bharat.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
42 minutes ago
- Mint
Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy
Zydus Lifesciences announced on Tuesday it is acquiring two biologics contract manufacturing facilities in California from US-based Agenus Inc for a total consideration of up to $125 million. The deal includes an upfront payment of $75 million, with the remaining $50 million to be paid over the following three years. The Ahmedabad-based pharmaceutical firm said the acquisition will establish its presence in the rapidly-expanding global biologics contract development and manufacturing organization (CDMO) sector. Zydus is also acquiring a 5.9% stake in Agenus for $16 million, through its wholly-owned subsidiary Zynext Ventures USA LLC, it said in an exchange filing on Tuesday. The drugmaker has also entered into a licensing agreement with Agenus to commercialise its investigational Botensilimab (BOT) and Balstilimab (BAL) combination therapy in India and Sri Lanka. Agenus is a clinical-stage immuno-oncology company committed to developing immune therapies against cancer. The move to acquire biologics manufacturing facilities in the US aligns with Zydus' strategic focus on biologics as a key growth driver this year. Also Read: Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial "The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California," managing director Sharvil Patel said in a statement. 'This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry," he added. Additionally, the acquisition gives the company a stronger manufacturing presence in the US, amid ongoing uncertainties over potential American tariffs on pharmaceutical imports. In the company's earnings call last month, Patel had said the company is evaluating opportunities for local manufacturing in the US. 'We have committed to making a good amount of investments in the US with our foray into specialty and other areas," he told investors. Exclusive manufacturer to Agenus Under the terms of the agreement, Zydus will acquire two modern biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and contingent payment of $50 million to be paid over three years subject to achievement of certain revenue milestone. The acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and a foothold in California, a leading global biotech hub. The move also enables Zydus to 'leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally," it said in the release. Also Read: KKR provides $600 mn financing to Manipal Group to fuel its corporate expansion The CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. As part of the transaction, Zydus will become the exclusive contract manufacturer for Agenus, and provide manufacturing services for the clinical and commercial supply of two identified Phase-3 ready immuno-oncology products - Botensilimab and Balstilimab. Zydus will also have the first right of negotiation to manufacture any of the future pipeline products by Agenus. Agenus reported a turnover of $103.46 million in 2024, according to the exchange filing. Agenus' lead programme comprising Botensilimab and Balstilimab is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. The platform, which is currently in advanced clinical trials, has demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and patients who have undergone neoadjuvant, or primary, therapy. As part of the licensing agreement inked with Agenus, Zydus will be responsible for clinical development and regulatory approvals of the licensed products in India and Sri Lanka and will pay 5% royalty on net sales upon successful approval and commercialization. Also Read: Young heirs take charge as Indian pharma firms plan succession Zydus will expand the reach of the therapy within its initial indications, as well as drive its expansion into other high unmet need indications and earlier lines of treatment, including primary treatments, the company said.
The Print
43 minutes ago
- The Print
Economically weaker sections, women will benefit from registration of Waqf properties: Jagdambika Pal
The BJP MP was the chairman of the Joint Committee of Parliament which had examined the contentious Waqf (Amendment) Bill introduced in the Lok Sabha in August last year and submitted its report to Lok Sabha Speaker Om Birla on January 30. Pal's remarks came against the backdrop of media reports that the Minority Affairs Ministry may soon launch the 'Umeed' portal for the registration of Waqf properties under the newly enacted law. New Delhi, Jun 3 (PTI) Pasmanda Muslims, women and children of the minority community will benefit from the registration of Waqf properties on a centralised platform under the Waqf (Amendment) Act, BJP MP Jagdamika Pal said on Tuesday. 'The name of that law that we passed is Umeed 2025… Now the Umeed Act is going to be launched under which (documents of) all Waqf properties will have to be uploaded (on the Umeed portal) within six months,' Pal told PTI Videos when asked about the likely launch of the portal. According to media reports, the 'Umeed' portal may be launched this week. However, there is no official confirmation on its schedule from the government. Pal said that the registration of Waqf properties on the centralised portal will stop their misuse and benefit economically weaker Pasmanda Muslims, women, children and others in the minority community. With the registration, the Minority Affairs Ministry will have 'complete information' about the total number of Waqf properties in the country, the BJP MP said. 'This will stop the misuse of Waqf,' he said, adding the Waqf properties were illegally sold earlier due to lack of information about them. The BJP leader said that the registration of Waqf properties on the portal will also increase their 'income' as the newly enacted law provides for their audit to be carried out by the auditors appointed by the Comptroller and Auditor General (CAG) of India. 'Its benefit will go to poor Pasmanda Muslims,' he added. The Waqf (Amendment) Act came into force with the Centre notifying it on April 8. The Lok Sabha and the Rajya Sabha passed the Waqf (Amendment) bill post-midnight on April 3 and April 4 respectively, and President Droupadi Murmu gave her assent to it on April 5. The Lok Sabha and the Rajya Sabha passed the Waqf (Amendment) bill post-midnight on April 3 and April 4 respectively, and President Droupadi Murmu gave her assent to it on April 5. The apex court is hearing several petitions related to the law. PTI PK RT This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Mint
44 minutes ago
- Mint
Yes Bank bulk deal: Carlyle group sells 2.6% stake in Yes Bank for ₹1,775 crore; stock down 10%
Global investment firm Carlyle group on Tuesday sold a 2.6 per cent stake in private sector lender Yes Bank for ₹ 1,775 crore through open market transactions. The development comes after State Bank of India and seven other lenders last month announced that they will sell 20 per cent of their combined stake in Yes Bank to Japan's Sumitomo Mitsui Banking Corporation for ₹ 13,483 crore. US-based Carlyle, through its affiliate CA Basque Investments, sold a total of 82 crore shares, representing a 2.62 per cent stake in Mumbai-based Yes Bank on the NSE and BSE, as per the bulk deal data on the bourses. The shares were disposed in the price range of ₹ 21.61-21.68 apiece, taking the combined transaction value to ₹ 1,774.89 crore. After the share sale, Carlyle's arm CA Basque Investments' holding in Yes Bank declined to 4.22 per cent from 6.84 per cent. Details of the buyers of Yes Bank's shares could not be ascertained on the BSE and the National Stock Exchange (NSE). Shares of Yes Bank declined 10.40 per cent to close at ₹ 20.85 apiece on the BSE, and it fell 10.01 per cent to settle at ₹ 20.95 per piece on the NSE. Last month, SBI and seven other lenders announced that they will sell 20 per cent of their combined stake in Yes Bank to Japan's SMBC for a consideration of ₹ 13,483 crore, making it the largest cross-border investment in the Indian banking sector. Following the completion of the transaction, SMBC will become the single-largest shareholder of Mumbai-based Yes Bank. Of the 20 per cent stake, SBI will dilute a 13.19 per cent stake in Yes Bank in favour of SMBC for a consideration of ₹ 8,889 crore, while 6.81 per cent shareholding will be offloaded by seven other lenders, including Axis Bank, Bandhan Bank, Federal Bank, HDFC Bank, ICICI Bank, IDFC First Bank and Kotak Mahindra Bank for about ₹ 4,594 crore. SBI and the seven investor lenders had invested in the bank as part of the YES Bank Reconstruction Scheme in March 2020. Mumbai-headquartered SBI, which owned a 24 per cent stake in Yes Bank, will be left with a little over 10 per cent stake after the dilution. SMBC is a wholly-owned subsidiary of Sumitomo Mitsui Financial Group, Inc (SMFG). SMFG is the second largest banking group in Japan with total assets of USD 2 trillion as of December 2024 with strong global presence. For the fourth quarter ended March 2025, Yes Bank reported a 63 per cent jump in standalone net profit at ₹ 738 crore as compared to ₹ 451.9 crore in the corresponding quarter a year ago. In FY25, the bank's net profit doubled to ₹ 2,406 crore compared to ₹ 1,251 crore in the preceding fiscal year.
